Literature DB >> 2984399

Renal toxicity of cisplatin in children.

R B Womer, J Pritchard, T M Barratt.   

Abstract

We measured renal function in 22 children receiving cisplatin as initial treatment for neuroblastoma or malignant germ cell tumors. Glomerular filtration rates were estimated from the plasma clearance of 51Cr-EDTA and were compared with measurements of plasma creatinine concentration and creatinine clearance. The degree of cisplatin-induced renal damage varied widely, and plasma creatinine measurements and creatinine clearances were not reliable guides to glomerular filtration rate. Renal function in children receiving cisplatin should be monitored by measurement of glomerular filtration rate with an isotope clearance technique.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984399     DOI: 10.1016/s0022-3476(85)80098-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  28 in total

Review 1.  Childhood cancer: cure at what cost?

Authors:  P H Morris-Jones; A W Craft
Journal:  Arch Dis Child       Date:  1990-06       Impact factor: 3.791

Review 2.  Genitourinary long-term outcomes for childhood cancer survivors.

Authors:  Margarett Shnorhavorian; Debra L Friedman; Martin A Koyle
Journal:  Curr Urol Rep       Date:  2009-03       Impact factor: 3.092

Review 3.  Renal late effects in patients treated for cancer in childhood: a report from the Children's Oncology Group.

Authors:  Deborah P Jones; Sheri L Spunt; Daniel Green; James E Springate
Journal:  Pediatr Blood Cancer       Date:  2008-12       Impact factor: 3.167

4.  Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.

Authors:  J K Duong; G J Veal; C E Nath; P J Shaw; J Errington; R Ladenstein; A V Boddy
Journal:  Br J Clin Pharmacol       Date:  2018-11-04       Impact factor: 4.335

5.  Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group.

Authors:  Wendy Landier; Kristin Knight; F Lennie Wong; Jin Lee; Ola Thomas; Heeyoung Kim; Susan G Kreissman; Mary Lou Schmidt; Lu Chen; Wendy B London; James G Gurney; Smita Bhatia
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

6.  Hypomagnesaemia and hypocalcaemia after treatment with mitoxantrone.

Authors:  K D Griffiths; D H Parry
Journal:  BMJ       Date:  1988-08-13

7.  Fanconi syndrome after ifosfamide.

Authors:  M Moncrieff; A Foot
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Renal function following unilateral nephrectomy for neuroblastoma and Wilms' tumour.

Authors:  M Schell; P Cochat; A Hadj-Aïssa; E Bouffet; L Dubourg; M Brunat-Mentigny
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

9.  Proceedings of the American Society of Pediatric Nephrology 1993 Education Symposium, Washington, D.C., 4 May, 1993.

Authors: 
Journal:  Pediatr Nephrol       Date:  1994-10       Impact factor: 3.714

Review 10.  Cytostatics--induced tubular toxicity.

Authors:  M Brandis; K von der Hardt; R B Zimmerhackl; M Mohrmann; J Leititis
Journal:  Clin Investig       Date:  1993-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.